Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Goodwill (2018 - 2025)

Silence Therapeutics' Goodwill history spans 8 years, with the latest figure at $10.6 million for Q4 2025.

  • On a quarterly basis, Goodwill rose 13.09% to $10.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $10.6 million, a 13.09% increase, with the full-year FY2025 number at $10.6 million, up 13.09% from a year prior.
  • Goodwill hit $10.6 million in Q4 2025 for Silence Therapeutics, roughly flat from $10.6 million in the prior quarter.
  • Over the last five years, Goodwill for SLN hit a ceiling of $10.9 million in Q2 2021 and a floor of $9.4 million in Q3 2022.
  • Historically, Goodwill has averaged $10.0 million across 5 years, with a median of $9.8 million in 2025.
  • Biggest five-year swings in Goodwill: decreased 12.62% in 2022 and later rose 13.09% in 2025.
  • Tracing SLN's Goodwill over 5 years: stood at $10.2 million in 2021, then fell by 8.21% to $9.4 million in 2022, then rose by 3.58% to $9.7 million in 2023, then dropped by 3.48% to $9.4 million in 2024, then grew by 13.09% to $10.6 million in 2025.
  • Business Quant data shows Goodwill for SLN at $10.6 million in Q4 2025, $10.6 million in Q3 2025, and $10.6 million in Q2 2025.